Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James S Olver

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The Medical Journal of Australia|November 6, 2014
Depression and physical illnessJames S Olver, Malcolm J Hopwood
CNS Drugs|June 9, 2004
New formulations of existing antidepressants: advantages in the management of depressionTrevor R Norman, James S Olver
Neuropsychiatric Disease and Treatment|April 2, 2009
Duloxetine in the treatment of generalized anxiety disorderTrevor R Norman, James S Olver
Drug Design, Development and Therapy|April 7, 2010
Continuation treatment of major depressive disorder: is there a case for duloxetine?Trevor R Norman, James S Olver
The Australian and New Zealand Journal of Psychiatry|June 2, 2023
A challenge to the dopamine orthodoxy in schizophrenia?Trevor R Norman, James S Olver
Expert Opinion on Pharmacotherapy|March 12, 2021
Desvenlafaxine in the treatment of major depression: an updated overviewTrevor R Norman, James S Olver
Expert Opinion on Pharmacotherapy|February 14, 2019
Agomelatine for depression: expanding the horizons?Trevor R Norman, James S Olver
The Australian and New Zealand Journal of Psychiatry|August 26, 2023
Letters to the Editor: Author reply to Letters to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia?'Trevor R Norman, James S Olver
Expert Review of Neurotherapeutics|October 22, 2011
Duloxetine in the acute and continuation treatment of major depressive disorderLanny Bochsler, James S Olver, Trevor R Norman
Journal of Psychosomatic Research|July 8, 2021
Functional somatic syndromes and joint hypermobility: A systematic review and meta-analysisGrant Chen, James S Olver, Richard A Kanaan
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The Medical Journal of Australia|November 6, 2014
Depression and physical illnessJames S Olver, Malcolm J Hopwood
CNS Drugs|June 9, 2004
New formulations of existing antidepressants: advantages in the management of depressionTrevor R Norman, James S Olver
Neuropsychiatric Disease and Treatment|April 2, 2009
Duloxetine in the treatment of generalized anxiety disorderTrevor R Norman, James S Olver
Drug Design, Development and Therapy|April 7, 2010
Continuation treatment of major depressive disorder: is there a case for duloxetine?Trevor R Norman, James S Olver
The Australian and New Zealand Journal of Psychiatry|June 2, 2023
A challenge to the dopamine orthodoxy in schizophrenia?Trevor R Norman, James S Olver
Expert Opinion on Pharmacotherapy|March 12, 2021
Desvenlafaxine in the treatment of major depression: an updated overviewTrevor R Norman, James S Olver
Expert Opinion on Pharmacotherapy|February 14, 2019
Agomelatine for depression: expanding the horizons?Trevor R Norman, James S Olver
The Australian and New Zealand Journal of Psychiatry|August 26, 2023
Letters to the Editor: Author reply to Letters to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia?'Trevor R Norman, James S Olver
Expert Review of Neurotherapeutics|October 22, 2011
Duloxetine in the acute and continuation treatment of major depressive disorderLanny Bochsler, James S Olver, Trevor R Norman
Journal of Psychosomatic Research|July 8, 2021
Functional somatic syndromes and joint hypermobility: A systematic review and meta-analysisGrant Chen, James S Olver, Richard A Kanaan
Pageof 3